Hepatitis C Caring Ambassadors Program Newsletter

August 2005


In The News


Old View Slows Hepatitis C Fight (New Zealand)



4 Million People in Bangladesh Suffering From Hepatitis C Virus



Genelabs Drug Discovery Team Advances Compounds Against the Hepatitis C Virus in Preclinical Development



While Hep C infections climb dramatically, a downtown Hep C clinic struggles to find funding



Tarvacin(TM) starts with Phase I study against Hepatitis C Virus



Anadys Pharmaceuticals Announces Publication of Clinical Study of Isatoribine in Chronic Hepatitis C Demonstrating Proof of Concept



Star's fight for life



Reuse of syringes to withdraw saline from a common bag resulted in a massive outbreak of 99 new HCV infections at an independent hematology/oncology clinic in Nebraska



High-risk behaviors and increasing time of incarceration contribute to high prevalence of HCV infection in the prison population  



Most chronic hepatitis C sufferers will develop cirrhosis in later life.  Study suggests cirrhosis and liver disease nearly inevitable for people with hep C



A study examines the incidence and risk factors associated with Hepatitis C infection in rural Egypt.



Study: Injection Drug Use is Main HCV Risk in HIV



Hepatitis A Vaccine Urged for Hep C Patients



Hepatitis C co-infection blunts response to antiretroviral therapy



Nurse Shares Story of Hepatitis C, the 'Silent Epidemic'



[California] Senate Approves Needle-Exchange bill http://www.ukiahdailyjournal.com/Stories/0,1413,91~3089~3024165,00.html


Migenix to test hepatitis C drug



HIV-positive patients coinfected with HCV up to 80% more likely to die even with HIV treatment





Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Everson GT, et al. Hepatology. 2005 Aug;42(2):255-62.



Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. von Wagner M, et al. Gastroenterology. 2005 Aug;129(2):522-7.



Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Tamori A, et al. Am J Gastroenterol. 2005 Aug;100(8):1748-53.

Growth in the First 5 Years of Life is Unaffected in Children with Perinatally-acquired Hepatitis C Infection. European Paediatric Hcv Network. . J Pediatr. 2005 Aug;147(2):227-32

Diagnostic Discordance for Hepatitis C Virus Infection in Hemodialysis Patients.  Kalantar-Zadeh K, Miller LG, Daar ES. Am J Kidney Dis. 2005 Aug;46(2):290-300.

Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.  Inati A, et al. Br J Haematol. 2005 Aug;130(4):644-6.

Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.  Bargiggia S, et al.  Aliment Pharmacol Ther. 2005 Aug 1;22(3):209-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16091058&query_hl=7

Mood Alterations During Interferon-Alfa Therapy in Patients With Chronic Hepatitis C: Evidence for an Overlap Between Manic/Hypomanic and Depressive Symptoms. Constant A, et al.  J Clin Psychiatry. 2005 Aug;66(8):1050-1057.

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Zeuzem S, et al. J Hepatol. 2005 Aug;43(2):250-7.

Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function.  Hu KQ, et al. Am J Gastroenterol. 2005 Sep;100(9):2010-8.

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
Di Bisceglie AM, et. al. J. Hepatol. 2005 Sep;43(3):434-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16136646&dopt=Abstract

Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Piche T, et al. Gut. 2005 Aug;54(8):1169-73.       



Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Lok AS, et al. Hepatology. 2005 Aug;42(2):282-92.



Basic and Applied Science, Pre-Clinical Studies


Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Tang KH, et al. J Hepatol. 2005 Aug 31; [Epub ahead of print]



Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells.     Dansako H, Naka K, Ikeda M, Kato N. Biochem Biophys Res Commun. 2005 Aug 30; [Epub ahead of print]



Anterior cingulate activation and error processing during interferon-alpha treatment. Capuron L, et. al.  Biol Psychiatry. 2005 Aug 1;58(3):190-6.

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. Asahina Y, Izumi N, et al. J Hepatol. 2005 Oct;43(4):623-9.

Hepatitis C Virus Genotype 1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American and White Patients.  Layden-Almer JE, et al. J Infect Dis. 2005 Sep 15;192(6):1078-87. Epub 2005 Aug 12.


Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. Waris G, Siddiqui A. J Virol. 2005 Aug;79(15):9725-34.



Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses.     Abdalla MY, et al. J Med Virol. 2005 Aug;76(4):489-97.       



Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells. Garcia-Mediavilla MV, et al. J Hepatol. 2005 Oct;43(4):606-13.



The Expression of BCL-2 in Chronic Liver Diseases.  Mutluay R, et al. Saudi Med J. 2005 Aug;26(8):1245-9.


Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. Starkel P, De Saeger C, Leclercq I, Strain A, Horsmans Y. J Hepatol. 2005 Oct;43(4):687-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16098628&query_hl=7

CD8+ T Cell Depletion Amplifies Hepatitis C Virus Replication in Peripheral Blood Mononuclear Cells.  Li Y, et al. J Infect Dis. 2005 Sep 15;192(6):1093-101. Epub 2005 Aug 10.

Modulation of Vaccine-Induced Immune Responses to Hepatitis C Virus in Rhesus Macaques by Altering Priming before Adenovirus Boosting. Rollier C., et al.  J Infect Dis. 2005 Sep 1;192(5):920-9. Epub 2005 Aug 1.


In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.   Lin C J., et al.  Biol Chem. 2005 Aug 8; [Epub ahead of print]

Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site.  Di Marco S, et al.  J Biol Chem. 2005 Aug 19;280(33):29765-70. Epub 2005 Jun 13.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15955819&query_hl=10

Reduction of serum ghrelin concentration during interferon-alpha therapy in patients with chronic hepatitis C.   Watanabe H, et al. Hepatol Res. 2005 Aug 18; [Epub ahead of print]


HIV/HCV Coinfection


Failure of Hepatitis C Therapy in HIV-Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype.  Soriano V, et al.  J Infect Dis. 2005 Oct 1;192(7):1245-8. Epub 2005 Aug 24.

Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes.  Macias J, et al. Gut. 2005 Aug 23; [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16118349&query_hl=7

Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events.  Stebbing J, et al. Clin Infect Dis. 2005 Sep 15;41(6):906-11. Epub 2005 Aug 5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16107994&query_hl=7

Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection.  Hui CK, et al. J Clin Virol. 2005 Aug 12; [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16103008&query_hl=7

Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy.  Rockstroh JK,  et al.  J Infect Dis. 2005 Sep 15;192(6):992-1002. Epub 2005 Aug 11.


Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study.  Waters L, et al. Int J Cancer. 2005 Aug 10;116(1):161-3.


Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. Backus LI, et al. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-9.



Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Monto A, et al. Hepatology. 2005 Aug;42(2):310-6.



Complementary and Alternative Therapies


Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.  El-Zayadi AR, et al. Liver Int. 2005 Aug;25(4):746-51.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16086711&query_hl=7

Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. Ko WS, et al. World J Gastroenterol. 2005 Aug 14;11(30):4697-702.



Miscellaneous Works


Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Morrill JA, Shrestha M, Grant RW. J Gen Intern Med. 2005 Aug;20(8):754-8.



High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Campbell JV, et al. Drug Alcohol Depend. 2005 Aug 26; [Epub ahead of print]



Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Mathei C, et al. Eur J Clin Microbiol Infect Dis. 2005 Aug 19; [Epub ahead of print]



Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum. De Cock L, Hutse V, Vranckx R. Eur J Clin Microbiol Infect Dis. 2005 Aug 19; [Epub ahead of print]



Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Wang B, et al.  Transfusion. 2005 Jul;45(7):1089-96.


Geospatial analysis of hepatitis C in Connecticut: a novel application of a public health tool.
Trooskin SB
, Hadler J, St Louis T, Navarro et al. VJ. Public Health. 2005 Aug 4; [Epub ahead of print]

Patients' Experiences Related to Anti-viral Treatment for Hepatitis C.  Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patient Educ Couns. 2005 Aug 9; [Epub ahead of print]

Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.  Bini EJ, et al.   Am J Gastroenterol. 2005 Aug;100(8):1772-9

An assessment of hepatitis C virus infection among health-care workers of the National Cancer Institute of Naples, Southern Italy.  Montella M, et al. Eur J Public Health. 2005 Jul 21; [Epub ahead of print]
Determining the Extent of Quality Health Care for Hospitalized Patients with Cirrhosis.  Talwalkar JA.  Hepatology. 2005 Aug;42(2):492-4.

Cost comparison of two combination therapies with peginterferon alfa and ribavarin for the treatment of hepatitis C [Article in German] Telser H, Mulhaupt B, Helbling B, Zweifel P.  Schweiz Rundsch Med Prax. 2005 Aug 10;94(32):1207-14.


Intrafamilial transmission of hepatitis C in Egypt.  Mohamed MK, et al.  Hepatology. 2005 Jul 19; [Epub ahead of print]

ICSI for treatment of human immunodeficiency virus and hepatitis C virus-serodiscordant couples with infected male partner.  Mencaglia L, et al. Hum Reprod. 2005 Aug;20(8):2242-6. Epub 2005 Jun 9.


Community incidence of hepatitis B and C among reincarcerated women. Macalino GE, et al. Clin Infect Dis. 2005 Oct 1;41(7):998-1002. Epub 2005 Aug 30.



Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Colletta C, et al. Hepatology. 2005 Aug 24; [Epub ahead of print]



Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. Laperche S, et al. J Clin Microbiol. 2005 Aug;43(8):3877-83.



Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. Gerard C, et al. J Med Virol. 2005 Aug;76(4):503-10.